Document 0005
 DOCN  M9550005
 TI    Azole resistance in oropharyngeal Candida albicans strains isolated from
       patients infected with human immunodeficiency virus.
 DT    9505
 AU    He X; Tiballi RN; Zarins LT; Bradley SF; Sangeorzan JA; Kauffman CA;
       Department of Internal Medicine, University of Michigan Medical; School,
       Ann Arbor.
 SO    Antimicrob Agents Chemother. 1994 Oct;38(10):2495-7. Unique Identifier :
       AIDSLINE MED/95142605
 AB    For 212 oropharyngeal isolates of Candida albicans, the fluconazole MICs
       for 50 and 90% of strains tested were 0.5 and 16 micrograms/ml,
       respectively, and those of itraconazole were 0.05 and 0.2 micrograms/ml,
       respectively. Of 16 isolates for which fluconazole MICs were > 64
       micrograms/ml, itraconazole MICs for 14 were < or = 0.8 micrograms/ml
       and for 2 were > 6.4 micrograms/ml. Most fluconazole-resistant strains
       remained susceptible to itraconazole; whether itraconazole will prove
       effective for refractory thrush remains to be shown.
 DE    AIDS-Related Opportunistic Infections/*MICROBIOLOGY  Candida
       albicans/*DRUG EFFECTS  Drug Resistance, Microbial
       Fluconazole/*PHARMACOLOGY  Human  Itraconazole/*PHARMACOLOGY  Microbial
       Sensitivity Tests  Oropharynx/*MICROBIOLOGY  Support, Non-U.S. Gov't
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).